Page last updated: 2024-08-24

milnacipran and clozapine

milnacipran has been researched along with clozapine in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Morphy, R; Rankovic, Z1
Andricopulo, AD; Moda, TL; Montanari, CA1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Belmonte-de-Abreu, PS; Gama, CS; Lobato, MI; Picon, F; Zanatto, VC1

Reviews

2 review(s) available for milnacipran and clozapine

ArticleYear
Designed multiple ligands. An emerging drug discovery paradigm.
    Journal of medicinal chemistry, 2005, Oct-20, Volume: 48, Issue:21

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors

2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for milnacipran and clozapine

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:3

    Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results

2011
Efficacy of milnacipran in treating anxiety symptoms in schizophrenic patients receiving clozapine: a case series study.
    Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2006, Volume: 28, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Clozapine; Cyclopropanes; Female; Humans; Male; Milnacipran; Schizophrenia

2006